PRTAProthena Corporation plc

$549M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+620.6% YoY

Gross Profit

-$26M-2264.4% margin

Operating Income

-$38M-3290.9% margin

Net Income

-$36M-3147.4% margin

EPS (Diluted)

$-0.78

QoQ Revenue Growth

-1.6%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$37M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$581M

Total Liabilities

$143M

Stockholders' Equity

$439M

Cash & Equivalents

$543M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$160,000	+620.6%
Gross Profit	-$26M	-$21M	-24.4%
Operating Income	-$38M	-$32M	-18.2%
Net Income	-$36M	-$37M	+1.2%

Revenue Segments

US Rights and Global Rights

$85M77%

Collaboration Revenue, US Development Services

$24M22%

Collaboration

$1M1%

PRTA Q1 2022 Earnings — Prothena Corporation plc Revenue & Financial Results | Market Cap Arena